NASDAQ · GNFT
Genfit S.A.
Healthcare · Biotechnology
$8.95
Up+$0.35 (+4.07%)
Updated Sep 16, 2026, 7:06 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 283.59M
- P/E ratio
- -6.54
- Dividend yield
- 0.00%
- 52-week range
- $2.55 – $5.21
- Volume
- 56.95K
- Avg. volume
- 9.4K
Price performance
GNFT price history
1M range · 0 trading sessions · Daily adjusted prices
GNFT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest GNFT news
The latest Smart Investors Daily articles mentioning GNFT.
Stock researchCompany · Overview
GNFT research
Overview
Company profile and research snapshot.
Company profile
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 2, 2026 | ODDO BHF | Buy | — |
| Jun 28, 2026 | PORTZAMPARC BNP PARIBAS | Buy | — |
| Jun 17, 2026 | ESN/CIC MARKET SOLUTIONS | Buy | — |
| Mar 15, 2026 | LEERINK PARTNERS | Outperform | — |
| Feb 27, 2026 | ODDO BHF | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.
